Eagle Ridge Investment Management boosted its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 215.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,107 shares of the biopharmaceutical company’s stock after purchasing an additional 13,742 shares during the period. Eagle Ridge Investment Management’s holdings in Pfizer were worth $225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. Altfest L J & Co. Inc. lifted its position in Pfizer by 67.0% during the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after purchasing an additional 43,024 shares during the period. Sphera Funds Management LTD. acquired a new position in Pfizer during the first quarter valued at $13,342,000. Searle & CO. lifted its position in Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after purchasing an additional 38,500 shares during the period. Hartford Financial Management Inc. lifted its position in Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 835 shares during the period. Finally, Cadence Bank NA lifted its position in Pfizer by 1.4% during the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 1,428 shares during the period. Institutional investors own 69.01% of the company’s stock.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is currently owned by company insiders.
Shares of Pfizer, Inc. (PFE) opened at 35.06 on Wednesday. The stock has a market cap of $208.51 billion, a PE ratio of 25.65 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.78. The company’s 50-day moving average is $35.86 and its 200 day moving average is $33.92.
Pfizer (NYSE:PFE) last announced its earnings results on Monday, October 30th. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.03. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.61 earnings per share. Analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.65%. The ex-dividend date is Thursday, November 9th. Pfizer’s payout ratio is currently 94.12%.
PFE has been the subject of a number of research reports. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reiterated a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $38.32.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.